Ocular Surface Changes in Prostaglandin Analogue-Treated Patients
Glaucoma is the second leading cause of blindness globally. Reducing intraocular pressure (IOP) has been acknowledged to be the main therapy for glaucoma. Prostaglandin analogues (PGAs) have become the first-line therapy for patients with glaucoma due to their powerful efficacy for lowering (IOP). H...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2019/9798272 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564589996277760 |
|---|---|
| author | Wencui Shen Bingqing Huang Jin Yang |
| author_facet | Wencui Shen Bingqing Huang Jin Yang |
| author_sort | Wencui Shen |
| collection | DOAJ |
| description | Glaucoma is the second leading cause of blindness globally. Reducing intraocular pressure (IOP) has been acknowledged to be the main therapy for glaucoma. Prostaglandin analogues (PGAs) have become the first-line therapy for patients with glaucoma due to their powerful efficacy for lowering (IOP). However, usage of PGAs can also cause several notable side effects, including the changes in ocular surface. The relationship between PGAs and ocular surface changes is complicated and still remains unclear. In the present review, we summarize the recent studies of the effects of PGAs on ocular changes as well as the possible mechanisms that might provide new considerations during clinical medication. |
| format | Article |
| id | doaj-art-0d8015b54e574507a2fad19259665ca0 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-0d8015b54e574507a2fad19259665ca02025-02-03T01:10:42ZengWileyJournal of Ophthalmology2090-004X2090-00582019-01-01201910.1155/2019/97982729798272Ocular Surface Changes in Prostaglandin Analogue-Treated PatientsWencui Shen0Bingqing Huang1Jin Yang2Tianjin Eye Hospital & Eye Institute, Tianjin Key Laboratory of Ophthalmology and Visual Science, Nankai University, Tianjin, ChinaState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, ChinaTianjin Eye Hospital & Eye Institute, Tianjin Key Laboratory of Ophthalmology and Visual Science, Nankai University, Tianjin, ChinaGlaucoma is the second leading cause of blindness globally. Reducing intraocular pressure (IOP) has been acknowledged to be the main therapy for glaucoma. Prostaglandin analogues (PGAs) have become the first-line therapy for patients with glaucoma due to their powerful efficacy for lowering (IOP). However, usage of PGAs can also cause several notable side effects, including the changes in ocular surface. The relationship between PGAs and ocular surface changes is complicated and still remains unclear. In the present review, we summarize the recent studies of the effects of PGAs on ocular changes as well as the possible mechanisms that might provide new considerations during clinical medication.http://dx.doi.org/10.1155/2019/9798272 |
| spellingShingle | Wencui Shen Bingqing Huang Jin Yang Ocular Surface Changes in Prostaglandin Analogue-Treated Patients Journal of Ophthalmology |
| title | Ocular Surface Changes in Prostaglandin Analogue-Treated Patients |
| title_full | Ocular Surface Changes in Prostaglandin Analogue-Treated Patients |
| title_fullStr | Ocular Surface Changes in Prostaglandin Analogue-Treated Patients |
| title_full_unstemmed | Ocular Surface Changes in Prostaglandin Analogue-Treated Patients |
| title_short | Ocular Surface Changes in Prostaglandin Analogue-Treated Patients |
| title_sort | ocular surface changes in prostaglandin analogue treated patients |
| url | http://dx.doi.org/10.1155/2019/9798272 |
| work_keys_str_mv | AT wencuishen ocularsurfacechangesinprostaglandinanaloguetreatedpatients AT bingqinghuang ocularsurfacechangesinprostaglandinanaloguetreatedpatients AT jinyang ocularsurfacechangesinprostaglandinanaloguetreatedpatients |